China Approves Subcutaneous LEQEMBI for Early Alzheimer's Disease, Offering New Self-Administered Option

The National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation of LEQEMBI (lecanemab) for the initiation treatment of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia. This approval, based on Phase 3 data, introduces a new once-weekly, self-administered autoinjector option for patients, complementing the existing intravenous administration.